lysosomal disease

ly·so·so·mal dis·ease

a disease due to inadequate functioning of a lysosomal enzyme; most such diseases are associated with a storage disease.

ly·so·so·mal dis·ease

(lī'sō-sō'măl di-zēz')
A disease due to inadequate functioning of a lysosomal enzyme; most such diseases are associated with a storage disease.

ly·so·so·mal dis·ease

(lī'sō-sō'măl di-zēz')
Disorder due to inadequate functioning of a lysosomal enzyme.
References in periodicals archive ?
Infantile neuronal ceroid lipofuscinosis (INCL) is a severe lysosomal disease caused by mutations in the CLN1 gene, which encodes the soluble lysosomal enzyme Palmitoyl- Protein-Thioesterase-1 (PPT1) and result in osmiophilic granules accumulating in lysosomes and leading to neuroinflammation, neurodegeneration and death.
M1]-gagliosidosis is a relatively rare lysosomal disease, presenting clinically with progressive neurological deterioration mainly in infancy and childhood with various somatic manifestations.
Genzyme said on Friday that it has presented positive new data from its Phase 3 ENGAGE and ENCORE studies of its investigational oral therapy eliglustat tartrate for Gaucher disease type 1 at the 9th Annual Lysosomal Disease Network WORLD Symposium in Orlando, Fla.
In February 2010, the company announced Phase III data at the Lysosomal Disease Network's WORLD symposium.
M2 PHARMA-February 10, 2012-Synageva BioPharma presents positive interim data at eighth annual Lysosomal Disease Network (LDN) World Symposium(C)2012 M2 COMMUNICATIONS
Biopharmaceutical company Amicus Therapeutics (Nasdaq:FOLD) said on Thursday that the preclinical studies of its AT3375 for Gaucher disease were presented at the eighth Annual Lysosomal Disease Network WORLD Symposium (LDN WORLD).
Protalix BioTherapeutics Inc (NYSE:PLX) (AMEX:PLX) (TASE:PLX) announced on Thursday that new clinical data on taliglucerase alfa will be presented at the 8th Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2012 being held on 8-10 February in San Diego.
The results were presented for the first time this week at the Lysosomal Disease Network WORLD Symposium in Las Vegas, Nevada.
These two-year results were presented at the Lysosomal Disease Network WORLD Symposium earlier this year, Genzyme added.
These data will be presented at the Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2010, 10-12 February, in Miami, Florida.
Einat Brill Almon, the Company's Senior Vice President of Product Development, will be presenting at the WORLD Symposium 2009, co-organized by Lysosomal Disease Network and the National Institutes of Health.

Full browser ?